Back to top
more

Astrana Health, Inc. (ASTH)

(Real Time Quote from BATS)

$21.90 USD

21.90
294,566

+0.33 (1.53%)

Updated Aug 4, 2025 03:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ASTH vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

ASTH vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Wall Street Analysts Think Astrana Health, Inc. (ASTH) Could Surge 97.29%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in Astrana Health, Inc. (ASTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Zacks.com featured highlights Astrana Health, KT, Upbound, Noah Holdings and DXP Enterprises

by Zacks Equity Research

ASTH, KT, UPBD, NOAH, and DXPE all boast low EV-toEBITDA ratios and rising earnings estimates, making them standout value plays.

Zacks Equity Research

All You Need to Know About Astrana Health, Inc. (ASTH) Rating Upgrade to Strong Buy

by Zacks Equity Research

Astrana Health, Inc. (ASTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

ASTH or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ASTH vs. CHE: Which Stock Is the Better Value Option?

Anindya Barman headshot

Tap These 5 Bargain Stocks With Alluring EV-to-EBITDA Ratio

by Anindya Barman

ASTH, KT, UPBD, NOAH and DXPE stand out with low EV-to-EBITDA ratios and strong 2025 earnings growth forecasts.

Zacks Equity Research

New Strong Buy Stocks for July 10th

by Zacks Equity Research

ASTH, LGCY, STM, BAYRY and KD have been added to the Zacks Rank #1 (Strong Buy) List on July 10, 2025.

Zacks Equity Research

New Strong Sell Stocks for June 4th

by Zacks Equity Research

ASLE, ASTH and MITT have been added to the Zacks Rank #5 (Strong Sell) List on May 4 2025.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Astrana Health Stock?

by Zacks Equity Research

Investors need to pay close attention to ASTH stock based on the movements in the options market lately.

Zacks Equity Research

Astrana Health, Inc. (ASTH) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of -39.13% and 2.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

U.S. Physical Therapy (USPH) Beats Q1 Earnings Estimates (Revised)

by Zacks Equity Research

U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 4.35% and 3.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

U.S. Physical Therapy (USPH) Lags Q1 Earnings Estimates

by Zacks Equity Research

U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of -10.87% and 3.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Astrana Health, Inc. (ASTH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Astrana Health, Inc. (ASTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Implied Volatility Surging for Astrana (ASTH) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Astrana (ASTH) stock based on the movements in the options market lately.

Zacks Equity Research

Elanco Animal Health (ELAN) Soars 12.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Elanco Animal Health (ELAN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Astrana Health, Inc. (ASTH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of -266.67% and 5.42%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Encompass Health (EHC) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Encompass Health (EHC) delivered earnings and revenue surprises of 14.71% and 2.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quest Diagnostics (DGX) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 1.83% and 1.96%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in RadNet (RDNT): Can Its 5.9% Jump Turn into More Strength?

by Zacks Equity Research

RadNet (RDNT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

ADUS vs. ASTH: Which Stock Is the Better Value Option?

by Zacks Equity Research

ADUS vs. ASTH: Which Stock Is the Better Value Option?

Zacks Equity Research

Astrana Health, Inc. (ASTH) Meets Q3 Earnings Estimates

by Zacks Equity Research

Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of 0% and 3.61%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

EHC or ASTH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EHC vs. ASTH: Which Stock Is the Better Value Option?

Zacks Equity Research

U.S. Physical Therapy (USPH) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 1.47% and 2.48%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

RadNet (RDNT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

RadNet (RDNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Astrana Health, Inc. (ASTH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Astrana Health, Inc. (ASTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.